田聪, 汤丽娜, 林峰, et al. Expression and clinical significance of PAK5 protein expression in osteosarcoma[J]. China Oncology, 2014, 24(1): 1-7. DOI: 10.3969/j.issn.1007-3969.2014.01.001.
Expression and clinical significance of PAK5 protein expression in osteosarcoma
Background and purpose: p21-activated kinase 5 (PAK5) is a recently identified member of PAKs that regulate many intracellular processes such as cytoskeleton remodeling
cell proliferation
cell differentiation
gene transcription and cell apoptosis. Recently
studies found that PAK5 was overexpressed in some cancer such as gastric and colon cancer. However
the expression status and biological function of PAK5 in osteosarcoma are not clearly known. The objective of this study was to investigate the expression of PAK5 in osteosarcoma tissue and their relationships with the prognosis of osteosarcoma. Methods: The expression of PAK5 was detected by using immunohistochemical method in 92 specimens of human osteosarcoma tissues and 33 cases of osteoclastoma tissue
respectively. Results: The positive rate of PAK5 was 71.7% (66/92) in all the 92 cases of osteosarcoma. PAK5 expressions were not related to clinical variables such as gender
age
tumor location
tumor size
histological type and local recurrence
but significantly related to Enneking grade
tumor cell necrosis rate and lung metastasis
and the high expression of PAK5 may reduce the efficiency of chemotherapy. Survival analysis indicated that high expression of PAK5 correlated with poor prognosis of patients with osteosarcoma. Univariate survival analysis showed that the significant prognostic factors were tumor size
Enneking grade
local recurrence
lung metastasis and expression levels of PAK5. COX multivariate regression identified that the PAK5 expression levels (P=0.001) and lung metastasis (P=0.015) were independent prognostic factors of patients with osteosarcoma. Conclusion: The positive expressions of PAK5 closely correlate with Enneking grade
tumor cell necrosis rate and lung metastasis. Detection of PAK5 may be used as a molecular marker for prognosis of osteosarcoma. The high expression of PAK5 may reduce the efficiency of chemotherapy.